Journal: Frontiers in Oncology

Article Title: EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation

doi: 10.3389/fonc.2022.870721

Figure Lengend Snippet: (A–I) Protein expression levels of target genes (BIN3, DCTN6, DMTN, KBTBD11, EPHX2, TXNL1, ANAT1, PPP2CB, and VPS37A) were negatively correlated with the TNM stage of CRC (n = 297 (stage I: 28, stage II: 120, stage III: 125, stage IV: 24). Wilcoxon’s test was used to compare groups. n.s, not significant; *p < 0.05,**p < 0.01,***p < 0.001,****p < 0.0001.

Article Snippet: The anti-EPHX2 antibody was purchased from ProteinTech (Ag1283).

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation

doi: 10.3389/fonc.2022.870721

Figure Lengend Snippet: GSEA enrichment analysis and protein interaction network of target genes. (A–D) Three optimal enrichment signaling pathways were screened according to NES >2 and FDR <0.001. (E) PPI analysis of enrichment pathway genes and target genes was performed using the String online tool (highest confidence: 0.9). (F) MCC was used to screen for core node, and EPHX2 was the first target gene to appear in the core node (top 12).

Article Snippet: The anti-EPHX2 antibody was purchased from ProteinTech (Ag1283).

Techniques: Protein-Protein interactions

Journal: Frontiers in Oncology

Article Title: EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation

doi: 10.3389/fonc.2022.870721

Figure Lengend Snippet: The protein expression profile of EPHX2 in human CRC tumor tissues (tumor) and adjacent normal tissues (adjacent). (A) The expression of EPHX2 in human CRC tumor tissues. (B) The expression of EPHX2 in adjacent normal tissues. (C) The expression of EPHX2 protein profile was significantly lower in tumor cells than in adjacent cells (paired t-test, n = 158, ***p < 0.001; original magnification, 200×; scale bars, 200 μm).

Article Snippet: The anti-EPHX2 antibody was purchased from ProteinTech (Ag1283).

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation

doi: 10.3389/fonc.2022.870721

Figure Lengend Snippet: EPHX2 low expression cell line screening, cell transfection, and phenotypic determination. (A) HCT116 cells with low background expression of EPHX2 were selected for stable overexpression of EPHX2. (B) Detection of WB after stable transfection of EPHX2 overexpression into HCT116. (C) Invasion in the EPHX2 overexpression HCT116 cells was inhibited, and this effect can be reversed by EPHX2-siRNA co-transfection. ANOVA was used to compare the mean values of relative cell numbers between the two groups. * p < 0.05, ** p < 0.01; original magnification, 10×; scale bars, 50 μm. (D) Cell apoptosis was promoted in EPHX2 overexpression group, and co-transfection with siRNA can reverse this effect. Statistical significance was determined with ANOVA. *** p < 0.001, **** p < 0.0001.

Article Snippet: The anti-EPHX2 antibody was purchased from ProteinTech (Ag1283).

Techniques: Expressing, Transfection, Over Expression, Stable Transfection, Cotransfection

Journal: Frontiers in Oncology

Article Title: EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation

doi: 10.3389/fonc.2022.870721

Figure Lengend Snippet: RNA-seq analysis of HCT116 cells stably transfected with EPHX2 overexpression. (A) Venn diagram ofoptimal enrichment KEGG pathway. (B) Finally, fatty acid degradation and peroxisome were labeled as EPHX2 as the core genes of the target gene set to inhibit the KEGG signaling pathway in the progression of CRC. The figure shows the results of cell RNA sequencing GSEA enrichment analysis after visualization using the ggplot2 R package.

Article Snippet: The anti-EPHX2 antibody was purchased from ProteinTech (Ag1283).

Techniques: RNA Sequencing, Stable Transfection, Transfection, Over Expression, Labeling

Journal: Frontiers in Oncology

Article Title: EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation

doi: 10.3389/fonc.2022.870721

Figure Lengend Snippet: Lipid drop Oil Red O staining and detection of ROS in HCT116 cells. (A) Lipid drop Oil Red O staining in EPHX2-NC group. (B) Lipid drop Oil Red O staining in EPHX2-OE group. (C) The area (Obj./total: the red stain occupying the total area of visual field) was calculated using ImageJ pro plus6, which randomly selected high, medium, and low ORO staining images from each of the three repeated experiments. Statistical significance was determined with ANOVA. Compared with the EPHX2-NC group, the EPHX2-OE group had decreased ROS level. * p < 0.05; original magnification, 100×; scale bars, 100μm. (D) ROS in the two groups was detected using the enzyme labeling instrument. ANOVA was used to compare the mean values after absorbance conversion. Compared with the EPHX2-NC group, the EPHX2-OE group had increased ROS level, ** p < 0.01.

Article Snippet: The anti-EPHX2 antibody was purchased from ProteinTech (Ag1283).

Techniques: Staining, Labeling

Journal: International Journal of Biological Sciences

Article Title: Neutrophil extracellular traps trigger alveolar epithelial cell necroptosis through the cGAS-STING pathway during acute lung injury in mice

doi: 10.7150/ijbs.99456

Figure Lengend Snippet: Antibody sources and dilutions.

Article Snippet: Rabbit anti-SP-C polyclonal antibody , Boster , A02001 , 1: 2000.

Techniques: Western Blot, Immunofluorescence, Polymer